Biological NTLA-2002
Biologic
Intellia TherapeuticsBiological NTLA-2002 is one of 45 biologic programs targeting Hereditary Angioedema. It is currently in development.
2
Indications
2
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Hereditary Angioedema
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Neoral
NovartisApproved
Firazyr
TakedaPhase 3
Lanoxin
AAdvanz Pharma
Approved
Andembry
CSL BehringApproved
Cyklokapron
AAmring
Phase 3
KALBITOR
TakedaPhase 3
C1 Esterase Inhibitor
TakedaPhase 3
Dawnzera (autoinjector)
Ionis PharmaceuticalsPhase 3
Ruconest
PPharming Technologies B.V.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biological NTLA-2002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Company